Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Deulorlatinib
2. Tgrx326
3. Tgrx-326
4. Gtpl13488
5. Compound Of Formula A [us20220024908a1]
| Molecular Weight | 409.4 g/mol |
|---|---|
| Molecular Formula | C21H19FN6O2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 0 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 110 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 700 |
| Isotope Atom Count | 3 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
68
PharmaCompass offers a list of Deulorlatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deulorlatinib manufacturer or Deulorlatinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deulorlatinib manufacturer or Deulorlatinib supplier.
PharmaCompass also assists you with knowing the Deulorlatinib API Price utilized in the formulation of products. Deulorlatinib API Price is not always fixed or binding as the Deulorlatinib Price is obtained through a variety of data sources. The Deulorlatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deulorlatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deulorlatinib, including repackagers and relabelers. The FDA regulates Deulorlatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deulorlatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Deulorlatinib supplier is an individual or a company that provides Deulorlatinib active pharmaceutical ingredient (API) or Deulorlatinib finished formulations upon request. The Deulorlatinib suppliers may include Deulorlatinib API manufacturers, exporters, distributors and traders.
Deulorlatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deulorlatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deulorlatinib GMP manufacturer or Deulorlatinib GMP API supplier for your needs.
A Deulorlatinib CoA (Certificate of Analysis) is a formal document that attests to Deulorlatinib's compliance with Deulorlatinib specifications and serves as a tool for batch-level quality control.
Deulorlatinib CoA mostly includes findings from lab analyses of a specific batch. For each Deulorlatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deulorlatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Deulorlatinib EP), Deulorlatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deulorlatinib USP).
